✦ LIBER ✦

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

✍ Scribed by Carol Aghajanian; John A. Blessing; Kathleen M. Darcy; Gary Reid; Koen DeGeest; Stephen C. Rubin; Robert S. Mannel; Jacob Rotmensch; Russell J. Schilder; William Riordan

Book ID: 113962168
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 589 KB
Volume: 115
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2009.07.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II evaluation of tirapazamine pl

A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

✍ Allan Covens; John Blessing; David Bender; Robert Mannel; Mark Morgan 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 101 KB

Phase II Trial of Pyrazoloacridine in Re

Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

✍ Steven C. Plaxe; John A. Blessing; Michael A. Bookman; William T. Creasman 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 39 KB

A phase II evaluation of mifepristone in

A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study

✍ Thomas F. Rocereto; William E. Brady; Mark S. Shahin; James S. Hoffman; Laurie S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 162 KB

A phase II study of two topotecan regime

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)

✍ Thomas J. Herzog; Michael W. Sill; Joan L. Walker; David O'Malley; Mark Shahin; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 240 KB

Phase II evaluation of dasatinib in the

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

✍ Russell J. Schilder; William E. Brady; Heather A. Lankes; James V. Fiorica; Mark 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 205 KB

Phase II Trial of Bevacizumab in Persist

Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

✍ Burger, R. A.; Sill, M. W.; Monk, B. J.; Greer, B. E.; Sorosky, J. I. 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 112 KB